Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics, Inc. (SERA) received a Rule 144 notice from stockholder Zhenya Lindgardt covering a planned sale of Class A common stock. The notice registers the potential sale of 20,139 shares, with an aggregate market value of $40,290, against total outstanding shares of 39,449,466 as of the notice. The seller states the transaction is to cover tax withholding obligations arising from restricted stock unit vesting and reflects the issuer’s election to satisfy such taxes through sell-to-cover transactions rather than a discretionary share sale.
Sera Prognostics, Inc. (SERA) received a Form 144 notice from officer Austin Aerts covering a planned sale of up to 13,591 shares of Class A Common Stock beginning on September 8, 2026. The shares relate to the vesting of restricted stock units and are being sold to fund tax withholding obligations through mandated sell-to-cover transactions, which the filing states are not discretionary.
Over the prior three months, Aerts reported additional sales of 5,440 shares on June 9, 2026 and 2,037 shares on June 11, 2026, also in Class A Common Stock.
SERA PROGNOSTICS, INC. (SERA) reports that Aerts Austin, previously identified as Chief Financial Officer, is no longer designated as an officer of the company within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934 as of August 31, 2026.
This Exit Form 4 contains no reported transactions and serves only to update the insider reporting status for Section 16 purposes.
SERA PROGNOSTICS, INC. (SERA) reported equity awards to Chief Financial Officer Scott Gleason on August 31, 2026. He received 117,924 RSUs, each representing one share of Class A common stock, and a stock option for 169,624 shares at an exercise price of $2.12 per share, expiring in 2036. Both awards vest over four years, with 25% vesting on September 10, 2027, and the remainder vesting in periodic installments thereafter, contingent on continued service.
SERA PROGNOSTICS, INC. (SERA) filed an initial statement of beneficial ownership (Form 3) for Scott Gleason, who serves as Chief Financial Officer. The filing reports no equity transactions or holdings at this time and includes a reference to a Power of Attorney authorizing certain filing-related actions.
Sera Prognostics, Inc. (SERA) announced a planned chief financial officer transition. The board appointed Scott Gleason as Chief Financial Officer and Treasurer, effective August 31, 2026, under an employment agreement and standard officer indemnification. Gleason, age 47, brings approximately 25 years of experience across diagnostics, life sciences, healthcare finance, investor relations, and corporate strategy, including senior roles at Neogen, NX Prenatal, LarmorBio, OraSure Technologies, and Myriad Genetics.
Current CFO and Treasurer Austin Aerts will step down on August 31, 2026 as part of the planned succession and will enter a consulting role. Under a Consulting Agreement effective September 8, 2026, he will provide services for twelve months at $375 per hour, with his existing employee stock options and restricted stock units continuing to vest during the consulting term and vested options remaining exercisable for three months afterward.
Sera Prognostics reported minimal revenue of $30 thousand for the quarter and $44 thousand for the first half of 2026, while operating expenses were $10.0 million for the quarter and $19.4 million year‑to‑date, resulting in a first‑half net loss of $17.5 million and an accumulated deficit of $329.3 million.
Cash and cash equivalents were $4.4 million and marketable securities were $75.9 million as of June 30, 2026, with total assets of $86.7 million and no debt beyond lease obligations. Management states that, after a restructuring and cost‑reduction program, existing cash resources are expected to fund operations through 2029.
To shift from a research‑heavy to a commercialization‑focused model for its PreTRM preterm‑birth test, Sera recorded $1.3 million of restructuring costs and reduced headcount by 18%, while planning material reductions in future research and general and administrative spending. Strategically, the company highlights new payer engagement, an Illinois Medicaid mandate for proteomic preterm‑birth testing, additional PRIME and AVERT clinical data, and a new $40.0 million at‑the‑market equity facility supporting potential future capital raises.
Sera Prognostics, Inc. reported second quarter 2026 results and business updates. Revenue for the quarter was $30,000, up from $17,000 a year earlier, while total operating expenses were $10.0 million. Net loss was $9.1 million compared with $8.0 million in the prior-year quarter, reflecting higher selling, marketing and general and administrative spending to support commercialization.
The company ended the quarter with $80.3 million in cash, cash equivalents and available-for-sale securities and stated this is expected to fund operations through significant adoption and commercialization milestones through 2029. Highlights included launch of a fourth partnership program for the PreTRM® Test with a state-based initiative and national payer, new Illinois legislation mandating Medicaid coverage for proteomic tests assessing preterm birth risk, additional PRIME trial data and recognitions, progress toward European CE marking with pre-application activities expected in the third quarter and submission in the fourth quarter of 2026, and strengthened commercial leadership and board expertise.
Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of 2,753,525 shares of Sera Prognostics, Inc. Class A common stock, representing 7.21% of that class as of June 30, 2026.
Both entities have shared voting and dispositive power over all reported shares, with no sole voting or dispositive power. abrdn Inc. holds the position on behalf of underlying clients through a parent holding company structure involving Aberdeen Group plc and abrdn Holdings Limited.
Phillips Joshua reported acquisition or exercise transactions in this Form 4 filing.
Sera Prognostics director Joshua Phillips received equity compensation awards on July 10, 2026. He was granted RSUs covering 2,260 and 22,426 Class A shares that vest on the earlier of July 10, 2027 or the next annual meeting, plus stock options for 3,477 and 34,494 shares at $1.97, vesting monthly over one year and expiring July 10, 2036, all contingent on continued service.